Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2017 (2017), Article ID 9684909, 9 pages
https://doi.org/10.1155/2017/9684909
Review Article

Tumor Lysis Syndrome in Patients with Hematological Malignancies

1Ethiopian Public Health Institute (EPHI), Addis Ababa, Ethiopia
2Department of Hematology & Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
3Department of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

Correspondence should be addressed to Bamlaku Enawgaw

Received 4 July 2017; Revised 1 October 2017; Accepted 12 October 2017; Published 2 November 2017

Academic Editor: Akira Hara

Copyright © 2017 Yohannes Belay et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. R. Hande and G. C. Garrow, “Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma,” American Journal of Medicine, vol. 94, no. 2, pp. 133–139, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Cairo and M. Bishop, “Tumour lysis syndrome: new therapeutic strategies and classification,” British Journal of Haematology, vol. 127, no. 1, pp. 3–11, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  4. W. Busakhala, M. D. Joshi, N. O. Abinya, A. Amayo, and H. O. Abwao, “Incidence of chemotherapy-related tumour lysis syndrome at Kenyatta National Hospital, Nairobi,” East African Medical Journal, vol. 84, no. 3, pp. 100–109, 2007. View at Google Scholar · View at Scopus
  5. T. Konuma, J. Ooi, S. Takahashi et al., “Fatal Acute tumor lysis syndrome following intrathecal chemotherapy for acute lymphoblastic leukemia with meningeal involvement,” Internal Medicine, vol. 47, no. 22, pp. 1987-1988, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Gogia, V. Raina, N. Iqbal, and V. Murugan, “Spontaneous tumor lysis syndrome in a patient of chronic lymphocytic leukemia,” Indian Journal of Medical and Paediatric Oncology, vol. 35, no. 1, p. 120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. H. Liu, F. Zhou, and X. L. Zhang, “Spontaneous Fatal Tumor Lysis Syndrome in a Patient with T-Cell Lymphoblastic Lymphoma/leukemia: successful treatment with continuous renal replacement therapy and increasing-dose gradually chemotherapy,” Journal of Clinical Case Reports, vol. 4, no. 5, 2014. View at Publisher · View at Google Scholar
  8. J. Bedrna and J. Polcák, “Actuary ureter closure after irradiation with x-rays for chronic leukemias,” Medizinische Klinik, vol. 25, pp. 1700-1701, 1929. View at Google Scholar
  9. Cairo M. S., S. Thompson, L. Stern, and S. Sherman, “Incidence of treatment-related, laboratory and clinical tumor lysis syndrome,” Blood, vol. 120, no. 21, article 238, 2012. View at Google Scholar
  10. A. E. Mirrakhimov, A. M. Ali, M. Khan, and A. Barbaryan, “Tumor lysis syndrome in solid tumors: an up to date review of the literature,” Rare Tumors, vol. 6, article 5389, no. 2, 2014. View at Publisher · View at Google Scholar
  11. S. C. Howard, D. P. Jones, and C.-H. Pui, “The tumor lysis syndrome,” The New England Journal of Medicine, vol. 364, no. 19, pp. 1844–1854, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Al Bagshi, E. S. Hassan, A. O. Sadek, and A. A. Abbas, “Tumor lysis syndrome in children with acute leukemia: Incidence and outcome,” Journal of Applied Hematology, vol. 4, no. 3, pp. 100–103, 2013. View at Publisher · View at Google Scholar
  13. G. R. Bahoush, E. Yazdi, S. H. Ansari, K. H. Arjmandi, and P. Vossough, “Identification of children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome,” Journal of Blood Disorders & Transfusion, vol. 6, no. 6, 2015. View at Google Scholar
  14. H. A. Abdel-Baset, E. N. Eldin, A. A. Eltayeb, and A. M. Hussein, “Clinical and laboratory approach for the identification of the risk for tumour lysis syndrome in children with acute lymphoblastic leukemia,” Life Science Journal, vol. 9, no. 1, pp. 189–195, 2012. View at Google Scholar · View at Scopus
  15. K. A. Blum, A. S. Ruppert, J. A. Woyach et al., “Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol,” Leukemia, vol. 25, no. 9, pp. 1444–1451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. B. Davidson, S. Thakkar, J. K. Hix, N. D. Bhandarkar, A. Wong, and M. J. Schreiber, “Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome,” American Journal of Medicine, vol. 116, no. 8, pp. 546–554, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Yarpuzlu, “A review of clinical and laboratory findings and treatment of tumor lysis syndrome,” Clinical chimical acta, vol. 333, no. 1, p. 13, 2003. View at Publisher · View at Google Scholar
  18. J. Terry, “The major electrolytes: Sodium, potassium, and chloride,” Journal of Intravenous Nursing, vol. 17, no. 5, pp. 240–247, 1994. View at Google Scholar · View at Scopus
  19. C. D. Flombaum, “Metabolic emergencies in the cancer patient,” Seminars in Oncology, vol. 27, no. 3, pp. 322–334, 2000. View at Google Scholar · View at Scopus
  20. A. J. Espay, “Neurologic complications of electrolyte disturbances and acid-base balance,” Handbook of Clinical Neurology, vol. 119, pp. 365–382, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. P. A. McCullough, T. M. Beaver, E. Bennett-Guerrero et al., “Acute and chronic cardiovascular effects of hyperkalemia: New insights into prevention and clinical management,” Reviews in Cardiovascular Medicine, vol. 15, no. 1, pp. 11–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. L. S. Weisberg, “Management of severe hyperkalemia,” Critical Care Medicine, vol. 36, no. 12, pp. 3246–3251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Bellinghieri, D. Santoro, and V. Savica, “Emerging drugs for hyperphosphatemia,” Expert Opinion on Emerging Drugs, vol. 12, no. 3, pp. 355–365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Álvarez-Lario and J. Macarrón-Vicente, “Uric acid and evolution,” Rheumatology, vol. 49, no. 11, pp. 2010–2015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Perry Wilson and J. S. Berns, “Onco-nephrology: Tumor Lysis syndrome,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 10, pp. 1730–1739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Shimada, R. J. Johnson, W. S. May et al., “A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome,” Nephrology Dialysis Transplantation , vol. 24, no. 10, pp. 2960–2964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Bosly, A. Sonet, C. R. Pinkerton et al., “Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study,” Cancer, vol. 98, no. 5, pp. 1048–1054, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Montesinos, I. Lorenzo, G. Martín et al., “Tumor lysis syndrome in patients with acute myeloid leukemia: Identification of risk factors and development of a predictive model,” Haematologica, vol. 93, no. 1, pp. 67–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Lahoti, H. Kantarjian, A. K. Salahudeen et al., “Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome,” Cancer, vol. 116, no. 17, pp. 4063–4068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Q. Lam and B. D. Humphreys, “Onco-nephrology: AKI in the cancer patient,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 10, pp. 1692–1700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Canet, L. Zafrani, J. Lambert et al., “Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival,” PLoS ONE, vol. 8, no. 2, Article ID e55870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Darmon, F. Vincent, L. Camous et al., “Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique,” British Journal of Haematology, vol. 162, no. 4, pp. 489–497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Y. Qunibi, “Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD),” Kidney International Supplements, vol. 66, no. 90, pp. S8–S12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. T. C. Thomas, J. M. Smith, P. C. White, and S. Adhikari, “Transient neonatal hypocalcemia: Presentation and outcomes,” Pediatrics, vol. 129, no. 6, pp. e1461–e1467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Skugor, “Hypocalcemia,” Frontline Medical News, 2014.
  36. V. Kaur, P. Mehta, J. Johnsurd, and R. Govindarajan, “Ibrutinib-associated tumor Lysis syndrome in a patient with chronic lymphocytic Leukemia,” Blood, vol. 124, no. 23, pp. 3503–3505, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Opyrchal, T. Figanbaum, A. Ghosh, V. Rajkumar, and S. Caples, “Spontaneous Tumor Lysis Syndrome in the Setting of B-Cell Lymphoma,” Case Reports in Medicine, vol. 2010, Article ID 610969, 3 pages, 2010. View at Publisher · View at Google Scholar
  38. A. C. Weeks and M. E. Kimple, “Spontaneous Tumor Lysis Syndrome,” Journal of Investigative Medicine High Impact Case Reports, vol. 3, no. 3, p. 232470961560319, 2015. View at Publisher · View at Google Scholar
  39. F. Wasim, A. M. Khaskheli, A. A. Siddiqui, O. Tariq, and M. A. Ansari, “Tumour lysis syndrome in haematological malignancies,” Journal of the Liaquat University of Medical and Health Sciences, vol. 11, no. 2, pp. 84–89, 2012. View at Google Scholar · View at Scopus
  40. B. Sevinir, M. Demirkaya, B. Baytan, and A. M. Günë, “Hyperuricemia and tumor lysis syndrome in children with non-Hodgkin's lymphoma and acute lymphoblastic leukemia,” Turkish Journal of Hematology, vol. 28, no. 1, pp. 52–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Ahsan Ejaz, N. Pourafshar, R. Mohandas, B. A. Smallwood, R. J. Johnson, and J. W. Hsu, “Uric acid and the prediction models of tumor lysis syndrome in AML,” PLoS ONE, vol. 10, no. 3, Article ID e0119497, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Wössman, M. Schrappe, U. Meyer, M. Zimmermann, and A. Reiter, “Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase,” Annals of Hematology, vol. 82, no. 3, pp. 160–165, 2003. View at Google Scholar · View at Scopus
  43. M. S. Cairo, B. Coiffier, A. Reiter, and A. Younes, “Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus,” British Journal of Haematology, vol. 149, no. 4, pp. 578–586, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Tosi, G. Barosi, C. Lazzaro et al., “Consensus conference on the management of tumor lysis syndrome,” Haematologica, vol. 93, no. 12, pp. 1877–1885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. A. R. Mato, B. E. Riccio, L. Qin, D. F. Heitjan, M. Carroll, and A. Loren, “A predictive model for the detection of tumor lysis syndrome during AML induction therapy,” Leukemia & lymphoma, vol. 47, no. 5, pp. 877–83, 2006. View at Publisher · View at Google Scholar
  46. C. Esposito, A. R. Plati, T. Mazzullo et al., “Renal function and functional reserve in healthy elderly individuals,” Journal of Nephrology, vol. 20, no. 5, pp. 617–625, 2007. View at Google Scholar · View at Scopus
  47. T. H. Truong, J. Beyene, J. Hitzler et al., “Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome,” Cancer, vol. 110, no. 8, pp. 1832–1839, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. P. J. Galardy, J. Hochberg, S. L. Perkins, L. Harrison, S. Goldman, and M. S. Cairo, “Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: A Children's Oncology Group Report,” British Journal of Haematology, vol. 163, no. 3, pp. 365–372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Minasyan and M. Henrici, “Tumor Lysis Syndrome in Light Chain Multiple Myeloma Treated with Bortezomib Combination Therapy,” The Medicine Forum, vol. 16, no. 18, pp. 43–45, 2015. View at Google Scholar
  50. E. Terpos, M. Politou, and A. Rahemtulla, “Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 10, pp. 623–625, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Alavi, M. T. Arzanian, M. R. Abbasian, and Z. Ashena, “Tumor lysis syndrome in children with non-hodgkin lymphoma,” Pediatric Hematology and Oncology, vol. 23, no. 1, pp. 65–70, 2009. View at Publisher · View at Google Scholar
  52. S. C. Howard, S. Trifilio, T. K. Gregory, N. Baxter, and A. McBride, “Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review,” Annals of Hematology, vol. 95, no. 4, pp. 563–573, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Coiffier, A. Altman, C.-H. Pui, A. Younes, and M. S. Cairo, “Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2767–2778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Rampello, T. Fricia, and M. Malaguarnera, “The management of tumor lysis syndrome,” Nature Clinical Practice Oncology, vol. 3, no. 8, pp. 438–447, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. C. LaRosa, L. McMullen, S. Bakdash et al., “Acute renal failure from xanthine nephropathy during management of acute leukemia,” Pediatric Nephrology, vol. 22, no. 1, pp. 132–135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. V. M. Pais Jr., G. Lowe, C. D. Lallas, G. M. Preminger, and D. G. Assimos, “Xanthine urolithiasis,” Urology, vol. 67, no. 5, pp. 1084.e9–1084.e11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Cortes, J. O. Moore, R. T. Maziarz et al., “Control of plasma uric acid in adults at risk for tumor lysis syndrome: Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - Results of a multicenter phase III study,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4207–4213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. S. C. Goldman, J. S. Holcenberg, J. Z. Finklestein et al., “A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis,” Blood, vol. 97, no. 10, pp. 2998–3003, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. D. K. L. Cheuk, A. K. S. Chiang, G. C. F. Chan, and S. Y. Ha, “Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.,” Cochrane Database of Systematic Reviews, vol. 8, p. CD006945, 2014. View at Google Scholar · View at Scopus
  60. M. A. Lopez-Olivo, G. Pratt, S. L. Palla, and A. Salahudeen, “Rasburicase in tumor lysis syndrome of the adult: A systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 62, no. 3, pp. 481–492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. C.-H. Pui, H. H. Mahmoud, J. M. Wiley et al., “Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 697–704, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Jeha, H. Kantarjian, D. Irwin et al., “Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial,” Leukemia, vol. 19, no. 1, pp. 34–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Cammalleri and M. Malaguarnera, “Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout,” International Journal of Medical Sciences, vol. 4, no. 2, pp. 83–93, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. O. Bessmertny, L. M. Robitaille, and M. S. Cairo, “Rasburicase: A new approach for preventing and/or treating tumor lysis syndrome,” Current Pharmaceutical Design, vol. 11, no. 32, pp. 4177–4185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. L. A. Browning and J. A. Kruse, “Hemolysis and methemoglobinemia secondary to rasburicase administration,” Annals of Pharmacotherapy, vol. 39, no. 11, pp. 1932–1935, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. U. Ibrahim, A. Saqib, F. Mohammad, J. P. Atallah, and M. Odaimi, “Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know,” Journal of Oncology Pharmacy Practice, 2017. View at Publisher · View at Google Scholar
  67. C. M. Burns and R. L. Wortmann, “Gout therapeutics: New drugs for an old disease,” The Lancet, vol. 377, no. 9760, pp. 165–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Takai, T. Yamauchi, K. Fujita et al., “Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome,” Oncology Letters, vol. 8, no. 4, pp. 1523–1527, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Tamura, Y. Kawai, T. Kiguchi et al., “Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol,” International Journal of Clinical Oncology, vol. 21, no. 5, pp. 996–1003, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. H. R. Schumacher Jr., M. A. Becker, R. L. Wortmann et al., “Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial,” Arthritis Care & Research, vol. 59, no. 11, pp. 1540–1548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. E. M. Worcester and F. L. Coe, “Calcium kidney stones,” The New England Journal of Medicine, vol. 363, no. 10, pp. 954–963, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Hochberg and M. S. Cairo, “Tumor lysis syndrome: Current perspective,” Haematologica, vol. 93, no. 1, pp. 9–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Sallan, “Management of acute tumor lysis syndrome,” Seminars in Oncology, vol. 28, no. 2, pp. 9–12, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Jeha, “Tumor lysis syndrome,” Seminars in Hematology, vol. 38, no. 4, supplement 10, pp. 4–8, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Agha-Razii, S. L. Amyot, V. Pichette, J. Cardinal, D. Ouimet, and M. Leblanc, “Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia,” Clinical Nephrology, vol. 54, no. 1, pp. 59–63, 2000. View at Google Scholar · View at Scopus